```html

Keratopathy Secondary to Diabetes

Overview

Keratopathy secondary to diabetes refers to disease of the cornea (the clear front surface of the eye) that arises as a direct complication of diabetes mellitus. The condition encompasses several corneal abnormalities—most commonly diabetic keratopathy, which includes epithelial defects, delayed wound healing, reduced corneal sensitivity, and increased susceptibility to infection.

Both type 1 and type 2 diabetes can lead to keratopathy, but the risk rises with longer disease duration, poor glycemic control, and the presence of other diabetic eye complications such as diabetic retinopathy.

Worldwide, diabetes affects over 537 million adults (≈ 10 % of the global population) and is projected to rise to 783 million by 2045 (IDF, 2023). Up to 70 % of people with diabetes develop some form of ocular surface disease, and corneal complications are present in 30–60 % of these individuals, making diabetic keratopathy a significant public‑health concern.<sup>1,2</sup>

Symptoms

Symptoms may be subtle early on but can progress rapidly if the cornea is injured or infected. Common manifestations include:

• Blurred or fluctuating vision – often worse upon waking.
• Foreign‑body sensation – a feeling of grit or sand in the eye.
• Dryness or burning sensation – due to reduced tear film stability.
• Photophobia – sensitivity to light.
• Pain or tenderness – can range from mild discomfort to severe pain if an ulcer develops.
• Redness (conjunctival injection) – especially around the corneal margin.
• Recurrent epithelial erosions – episodes where the outermost corneal cells repeatedly slough off.
• Decreased corneal sensitivity – paradoxically, many patients report less feeling despite pain.
• Delayed healing of corneal abrasions – wounds that take days or weeks to close.
• Vision loss – if a stromal ulcer or scarring develops.

Because many of these signs mimic other ocular surface disorders, a thorough eye examination is essential.

Causes and Risk Factors

Pathophysiology

High blood glucose triggers several mechanisms that impair corneal health:

• Advanced glycation end‑products (AGEs) accumulate in the corneal stroma, altering collagen architecture and reducing transparency.
• Neuropathy – diabetic peripheral neuropathy also affects the trigeminal nerve, leading to reduced corneal sensitivity (neurotrophic keratopathy).
• Reduced epithelial cell turnover – hyperglycemia hampers limbal stem‑cell function, slowing regeneration.
• Altered tear film composition – osmotic changes and decreased mucin production cause dry‑eye symptoms.
• Impaired wound‑healing cascade – decreased expression of growth factors (e.g., epithelial growth factor, nerve growth factor) and abnormal inflammatory responses delay closure of epithelial defects.

Risk Factors

• Long‑standing diabetes (> 10 years).
• Poor glycemic control (HbA1c ≥ 8 %).
• Concurrent diabetic retinopathy or microvascular disease.
• Use of contact lenses (especially extended‑wear) which can exacerbate epithelial stress.
• Previous ocular surgery (e.g., cataract, LASIK) – corneal nerves are already compromised.
• Dry‑eye disease, autoimmune disorders (e.g., Sjögren’s), or use of topical glaucoma medications containing preservatives.
• Smoking and systemic hypertension, which further impair microcirculation.

Diagnosis

Diagnosis is clinical, supported by a battery of non‑invasive tests that evaluate the cornea’s structure, function, and surface integrity.

Eye‑Care Professional Examination

1. Slit‑lamp biomicroscopy – essential for visualizing epithelial defects, stromal edema, or infiltrates.
2. Fluorescein staining – highlights areas of epithelial loss; the pattern helps differentiate diabetic keratopathy from other erosive conditions.
3. Schirmer test & Tear Break‑Up Time (TBUT) – assess tear production and stability, common problems in diabetic eyes.
4. Corneal esthesiometry – measures corneal sensitivity; reduced values are typical in neurotrophic keratopathy.
5. Anterior segment optical coherence tomography (AS‑OCT) – provides cross‑sectional images of the cornea to evaluate thickness and edema.
6. In‑vivo confocal microscopy – visualizes nerve fiber density and epithelial cell morphology; useful for research and severe cases.

Laboratory & Systemic Evaluation

• HbA1c to gauge glycemic control.
• Serum lipid profile and blood pressure assessment (systemic risk modifiers).
• If infection is suspected, corneal scrapings for culture and sensitivity.

Treatment Options

Treatment combines medical therapy, procedural interventions, and strict systemic control of diabetes.

1. Optimizing Glycemic Control

• Target HbA1c < 7 % (individualized based on age, comorbidities).
• Collaboration with an endocrinologist or diabetes educator.

2. Ocular Surface Lubrication

• Preservative‑free artificial tears – use 4–6 times daily.
• Lubricating ointments or gels at night to maintain moisture.
• Consider punctal plugs for refractory dry eye.

3. Promoting Epithelial Healing

• Topical antibiotics (e.g., moxifloxacin 0.5 %) if a defect is present to prevent infection.
• Cycloplegic agents (e.g., homatropine) to reduce pain from ciliary spasm.
• Autologous serum eye drops** (20–50 %) – rich in growth factors and vitamin A, shown to accelerate epithelial closure in diabetic keratopathy.<sup>3</sup>
• Recombinant human nerve growth factor (cenegermin) – FDA‑approved for neurotrophic keratopathy, can improve corneal sensitivity and healing.
• Vitamin A ointment** (retinol palmitate 0.025 %) applied at night for persistent epithelial defects.

4. Anti‑Inflammatory & Immunomodulatory Therapy

• Short‑course topical steroids may be used for stromal inflammation, but beware of delayed wound healing.
• For chronic inflammation, cyclosporine A 0.05 % eye drops can improve tear production.

5. Procedural Interventions

• Bandage contact lens (BCL) – protects the cornea and promotes epithelial migration.
• Amniotic membrane transplantation – provides a biologic scaffold and anti‑inflammatory cytokines for non‑healing ulcers.
• Corneal debridement or superficial keratectomy to remove unhealthy epithelium.
• Phototherapeutic keratectomy (PTK) for superficial scarring.
• Laser‑assisted in‑situ keratomileusis (LASIK) reconsideration – patients with diabetic keratopathy are generally poor candidates for refractive surgery.

6. Systemic Adjuncts

• Oral omega‑3 fatty acids (EPA/DHA) can improve tear film quality.
• Control of hypertension and dyslipidemia reduces overall microvascular damage.

Living with Keratopathy Secondary to Diabetes

Daily Management Tips

• Adhere to a strict eye‑care routine – lubricate the eyes at least four times daily and re‑apply ointment before sleep.
• Avoid contact lenses until the cornea is stable; if they are required, use daily disposables with preservative‑free solutions.
• Protect your eyes – wear sunglasses that block UV and wind.
• Monitor blood sugar closely – rapid spikes or drops can worsen corneal symptoms.
• Schedule regular ophthalmology visits – at least annually, or more often if you have existing retinal disease.
• Keep a symptom diary: note any increase in redness, pain, or visual changes and report them promptly.
• Maintain a balanced diet rich in antioxidants (leafy greens, berries) and stay hydrated to support tear production.
• Limit alcohol and quit smoking, both of which impair wound healing.

Prevention

Preventing diabetic keratopathy hinges on systemic disease control and diligent ocular hygiene.

• Maintain HbA1c < 7 % (or target set by your provider).
• Attend all scheduled retinal screening appointments; detection of retinopathy often flags increased risk for corneal disease.
• Use preservative‑free artificial tears proactively, even when asymptomatic.
• Practice proper hand hygiene before touching the eyes or handling lenses.
• Replace eye makeup and applicators regularly to avoid bacterial contamination.
• Stay up‑to‑date on vaccinations (influenza, COVID‑19) because systemic infections can exacerbate ocular surface inflammation.

Complications

If left untreated, diabetic keratopathy can lead to serious outcomes:

• Corneal ulceration – can perforate, leading to a vision‑threatening emergency.
• Infectious keratitis – bacterial, fungal, or viral superinfection.
• Corneal scarring – permanent visual distortion.
• Persistent epithelial defects – may cause chronic pain and photophobia.
• Neurotrophic keratopathy progression – loss of corneal sensation can become irreversible.
• Secondary glaucoma due to chronic inflammation.

Studies indicate that up to 15 % of diabetic patients with persistent epithelial defects develop stromal ulceration within 6 months, underscoring the need for early intervention.<sup>4</sup>

When to Seek Emergency Care

Immediate medical attention is required if you experience any of the following:

• Sudden, severe eye pain or a feeling that something is stuck in the eye.
• Rapid worsening of vision (blurred, double, or loss of sight).
• Redness that spreads rapidly or is accompanied by swelling of the eyelid.
• Visible white or yellow spot on the cornea (possible ulcer).
• Discharge that is thick, pus‑like, or has a foul odor.
• Photophobia so intense that you cannot keep your eyes open.
• History of recent eye trauma or surgery combined with any of the above symptoms.

Do not wait—go to the nearest emergency department or call your eye‑care provider immediately.

---

© 2026 HealthGuide.org. All information provided is for educational purposes and does not replace professional medical advice. Consult an ophthalmologist or healthcare provider for personalized evaluation and treatment.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. 2023.
2. Mayo Clinic. “Diabetic eye disease.” Updated 2024. https://www.mayoclinic.org
3. Kim Y, et al. “Autologous serum eye drops for diabetic keratopathy: a systematic review.” Cornea. 2022;41(5): 643‑652.
4. Usta M, et al. “Incidence and risk factors of corneal ulceration in patients with diabetic keratopathy.” Ophthalmology. 2021;128(4):532‑540.
5. U.S. Food & Drug Administration. “Cenegermin (OXERVATE) prescribing information.” 2023.

```